explore -WSS

explore

author：comprehensive 2025-10-02 19:19:39 - browse：729

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

hotspot

WSS

Former Georgia lieutenant governor says he received grand jury subpoena

Medicare Advantage enrollment hits roughly 33.4 million

Former Georgia lieutenant governor says he received grand jury subpoena

As AI regulations shape up, health tech startups beg for clarity

Former Georgia lieutenant governor says he received grand jury subpoena

Medicare Advantage enrollment hits roughly 33.4 million

knowledge

explore

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Sage's campaign to raise awareness of postpartum depression hits a nerve

Affirmative action in medical school literally saved lives

Wegovy cuts risk of cardiovascular events by 20%, study finds

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Dobbs anniversary: the lost opportunity of abortion as health care

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Malaria cases in Florida and Texas: Here’s what you need to know

CDC launches VaccineFinder tool to locate Covid

hotspot

Biden praises World Series champion Astros for impact off the field during White House celebration

Judge rejects Trump's counterclaim against E. Jean Carroll

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Medicare Advantage enrollment hits roughly 33.4 million

More regulation could be coming for drug ads

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

hotspot

knowledge

hotspot

knowledge